Preclincial testing of Sorafenib and RAD001 in the Nfflox/flox;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

Drug discovery: Inhibitors that activate

(2010) Karen Cichowski et al.   NATURE

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Malignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathways

(2009) Daniela Katz et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Neurofibromatosis type 1

(2009) Kevin P. Boyd et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor

(2009) H. Huynh et al.   MOLECULAR CANCER THERAPEUTICS

Plexiform and Dermal Neurofibromas and Pigmentation Are Caused by Nf1 Loss in Desert Hedgehog-Expressing Cells

(2008) Jianqiang Wu et al.   CANCER CELL

Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow

(2008) Feng-Chun Yang et al.   CELL

How does the Schwann cell lineage form tumors in NF1?

(2008) Steven L. Carroll et al.   GLIA

Liquid chromatography–tandem mass spectrometric assay for sorafenib and sorafenib–glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite

(2008) Rolf W. Sparidans et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors

(2008) G. Johansson et al.   MOLECULAR CANCER THERAPEUTICS